{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:34:07Z","timestamp":1786696447977,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006048","name":"Universidad de la Rep\u00fablica Uruguay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006049","name":"Universidad de la Rep\u00fablica Comisi\u00f3n Sectorial de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["2309-347-2022"],"award-info":[{"award-number":["2309-347-2022"]}],"id":[{"id":"10.13039\/501100006049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.talanta.2026.130112","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:25:09Z","timestamp":1780759509000},"page":"130112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Luminescence-guided engineering of anti-idiotype nanobody-NanoLuc fusion reagents for sensitive monitoring of free therapeutic antibodies"],"prefix":"10.1016","volume":"310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-366X","authenticated-orcid":false,"given":"Adriana","family":"Carlomagno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9098-5688","authenticated-orcid":false,"given":"Paula","family":"Segovia-de los Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"P\u00edrez-Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-2230","authenticated-orcid":false,"given":"Alvaro","family":"Danza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Crampet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7675-7195","authenticated-orcid":false,"given":"Gabriel","family":"Lassabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gualberto","family":"Gonz\u00e1lez-Sapienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.talanta.2026.130112_bib1","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.talanta.2026.130112_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/abt\/tbac024","article-title":"The emergence of AntibodyPlus: the future trend of antibody-based therapeutics","volume":"5","author":"Zhu","year":"2022","journal-title":"Antibody Ther."},{"issue":"2","key":"10.1016\/j.talanta.2026.130112_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00216-025-06036-2","article-title":"Biopharmaceutical analysis \u2014 current analytical challenges, limitations, and perspectives","volume":"418","author":"Cunha","year":"2026","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.talanta.2026.130112_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.dmpk.2018.11.003","article-title":"Therapeutic drug monitoring of monoclonal antibodies: applicability based on their pharmacokinetic properties","volume":"34","author":"Imamura","year":"2019","journal-title":"Drug Metabol. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.talanta.2026.130112_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/cpt.278","article-title":"Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?","volume":"99","author":"Mould","year":"2016","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.talanta.2026.130112_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.211","article-title":"Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-alpha experience to oncology","volume":"99","author":"Oude Munnink","year":"2016","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.talanta.2026.130112_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tibtech.2025.07.003","article-title":"Challenges in realizing therapeutic antibody biosensing","volume":"44","author":"Nagata","year":"2026","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.talanta.2026.130112_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-0716-1186-9_18","article-title":"Recombinant anti-idiotypic antibodies in ligand binding assays for antibody drug development","volume":"2261","author":"Harth","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.talanta.2026.130112_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2024.113717","article-title":"Belimumab concentration measurements using a homologous anti-idiotype immunoassay","volume":"532","author":"Loeff","year":"2024","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.talanta.2026.130112_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.talanta.2015.05.010","article-title":"Anti-idiotypic nanobody: a strategy for development of sensitive and green immunoassay for Fumonisin B1","volume":"143","author":"Shu","year":"2015","journal-title":"Talanta"},{"issue":"22","key":"10.1016\/j.talanta.2026.130112_bib11","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1007\/s00216-016-9370-x","article-title":"A toxin-free enzyme-linked immunosorbent assay for the analysis of aflatoxins based on a VHH surrogate standard","volume":"408","author":"Wang","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"issue":"8","key":"10.1016\/j.talanta.2026.130112_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70089","article-title":"Adaptabodies: retargeting a predefined monoclonal antibody with bispecific nanobodies for antibody therapy","volume":"20","author":"Gonz\u00e1lez-Techera","year":"2025","journal-title":"Biotechnol. J."},{"issue":"2","key":"10.1016\/j.talanta.2026.130112_bib13","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1021\/acs.analchem.1c04603","article-title":"Bispecific single-domain antibodies as highly standardized synthetic calibrators for immunodiagnosis","volume":"94","author":"Segovia-de Los Santos","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.talanta.2026.130112_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fphar.2016.00027","article-title":"NanoLuc luciferase - a multifunctional tool for high throughput antibody screening","volume":"7","author":"Boute","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.talanta.2026.130112_bib15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/acs.bioconjchem.6b00112","article-title":"NanoLuc: a small luciferase is brightening up the field of bioluminescence","volume":"27","author":"England","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.talanta.2026.130112_bib16","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/cb3002478","article-title":"Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate","volume":"7","author":"Hall","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.talanta.2026.130112_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1220477","article-title":"A highly sensitive nanobody-based immunoassay detecting SARS-CoV-2 nucleocapsid protein using all-recombinant reagents","volume":"14","author":"Segovia-de Los Santos","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.talanta.2026.130112_bib18","article-title":"NanoB(2) to monitor interactions of ligands with membrane proteins by combining nanobodies and NanoBRET","volume":"3","author":"van den Bor","year":"2023","journal-title":"Cell Rep. Methods"},{"issue":"11","key":"10.1016\/j.talanta.2026.130112_bib19","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1021\/acssensors.4c01800","article-title":"BRET nano Q-Body: a nanobody-based ratiometric bioluminescent immunosensor for point-of-care testing","volume":"9","author":"Yang","year":"2024","journal-title":"ACS Sens."},{"key":"10.1016\/j.talanta.2026.130112_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jim.2017.07.006","article-title":"Development of NanoLuc bridging immunoassay for detection of anti-drug antibodies","volume":"450","author":"Nath","year":"2017","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.talanta.2026.130112_bib21","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1021\/acs.analchem.7b04601","article-title":"Recombinant peptidomimetic-nano luciferase tracers for sensitive single-step immunodetection of small molecules","volume":"90","author":"Ding","year":"2018","journal-title":"Anal. Chem."},{"issue":"18","key":"10.1016\/j.talanta.2026.130112_bib22","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1021\/ac201824z","article-title":"Competitive selection from single domain antibody libraries allows isolation of high-affinity antihapten antibodies that are not favored in the llama immune response","volume":"83","author":"Tabares-da Rosa","year":"2011","journal-title":"Anal. Chem."},{"issue":"18","key":"10.1016\/j.talanta.2026.130112_bib23","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1021\/acs.jafc.9b00688","article-title":"One-step ultrasensitive bioluminescent enzyme immunoassay based on nanobody\/nanoluciferase fusion for detection of Aflatoxin B(1) in cereal","volume":"67","author":"Ren","year":"2019","journal-title":"J. Agric. Food Chem."},{"issue":"7","key":"10.1016\/j.talanta.2026.130112_bib24","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bbagen.2015.03.009","article-title":"Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells","volume":"1850","author":"Rossotti","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.talanta.2026.130112_bib25","author":"Agency"},{"issue":"4","key":"10.1016\/j.talanta.2026.130112_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004888","article-title":"Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial","volume":"10","author":"Gehin","year":"2024","journal-title":"RMD Open"},{"issue":"14","key":"10.1016\/j.talanta.2026.130112_bib27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.talanta.2026.130112_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/BTT.S69606","article-title":"Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins","volume":"9","author":"Benucci","year":"2015","journal-title":"Biol. Targets & Ther."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003991402600768X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003991402600768X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:22:53Z","timestamp":1786695773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003991402600768X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"alternative-id":["S003991402600768X"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130112","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Luminescence-guided engineering of anti-idiotype nanobody-NanoLuc fusion reagents for sensitive monitoring of free therapeutic antibodies","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130112"}}